Pioneering the development of synthetic macrocyclic peptides.
Unlocking macrocyclic peptides for the most challenging drug targets, bridging the gap between small molecules and biologics.
Backed by world class investors and partners
01
Macrocyclic peptides have the best of both worlds
Antibody precision with small-molecule oral delivery, capable of targeting both intra- and extracellular pathways.
02
Nature’s valuable macrocycles have been used for decades
Yet only a few synthetic examples exist in the clinic. Efficient macrocyclic design unlocks a vast new modality.
03
At UNP, we’ve cracked the code
Born out of the Lokey Lab, the field leader in macrocycles, UNP has created the first platform to repeatably engineer synthetic macrocyclic peptides at scale.
04
A Scalable, Repeatable Platform
A continuous macrocycle optimization loop unites digital and physical lab technologies, iterating quickly and efficiently to more ”drug-like” macrocycles with each cycle.
Rapid optimization of potency, selectivity, and permeability
Iterative design, synthesis, and testing of synthetic macrocycles to rapidly generate permeable, highly potent, exquisitely selective, drug-like molecules.
Targeted Internal Portfolio
Our portfolio is focused on high value biology inaccessible to traditional small molecule approaches, leveraging our unique platform to deliver medicines for unmet medical needs.
Top Tier Partnerships
We’re partnering with industry leaders to unlock 'undruggable' targets through the power of macrocyclic peptides.
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
Merck & Co. signs $220M macrocyclic peptide deal after hailing ‘next wave of drug discovery’
Argenx signs $1.5B pact to turn Unnatural Products' macrocyclic peptides to 'undruggable' targets
